Key result
Platelet-activating factor (PAF) plays a dual role in adipose tissue, where natural PAF modulators may prevent obesity and potent PAF inhibitors may mitigate obesity-related metabolic dysfunctions.
Why the study?
The dual role of platelet-activating factor (PAF) in acute versus chronic obesity-associated inflammation and fat accumulation remains to be clarified.
This review highlights the dual role of platelet-activating factor in adipose tissue inflammation and suggests PAF modulators as potential therapeutic strategies for obesity-related metabolic dysfunction.
PAF's role in acute adipose inflammation may aid healthy remodeling; leaves open its therapeutic targeting in obesity.
Obesity, marked by excessive fat accumulation, especially abdominal, is a global health concern with significant public impact. While obesity-associated chronic unresolved inflammation contributes to metabolic dysfunctions, acute inflammation supports healthy adipose tissue remodeling and expansion. Platelet-activating factor (PAF), a "primitive" signaling molecule, is among the key mediators involved in the acute phase of inflammation and in various pathophysiological processes. This article explores the role of PAF in fat accumulation and obesity by reviewing experimental data from cell cultures, animals, and humans. It proposes an emerging biochemical mechanism in an attempt to explain its dual role in the healthy and obese adipose tissue, including also data on PAF's potential involvement in epigenetic mechanisms that may be linked to the "obesity memory". Finally, it highlights the potential of natural PAF modulators in promoting functional adipose tissue, thermogenesis, and obesity prevention through a healthy lifestyle, including a Mediterranean diet rich in PAF weak agonists/PAF receptor antagonists and regular exercise, which help maintain controlled PAF levels. Conversely, in cases of obesity-related systemic inflammation with excessive PAF levels, potent PAF inhibitors like ginkgolide B and rupatadine may help mitigate metabolic dysfunctions with PAFR antagonists potentially enhancing their effects synergistically.
No takes yet. Share an insight, caveat, or question.
Smaragdi Antonopoulou (2025) conducted a review in Obesity. Platelet-activating factor (PAF) was evaluated. Platelet-activating factor (PAF) plays a dual role in adipose tissue, where natural PAF modulators may prevent obesity and potent PAF inhibitors may mitigate obesity-related metabolic dysfunctions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: